PreveCeutical Medical Inc (PRVCF)

[JellyDonut]

NetworkNewsAudio Announces Audio Press Release (APR) on Exciting New Solutions to Tackle Pain

New York, New York--(Newsfile Corp. - February 5, 2018) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Promising New Approaches in Pain Management," featuring PreveCeutical Medical Inc. (OTCQB: PRVCF) (CSE: PREV) (FSE: 18H).

To hear the NetworkNewsAudio version, visit LINK

To read the original editorial, visit LINK

"Our preliminary work has highlighted that by using our proprietary linker technology we can enhance stability while maintaining, and in some cases enhancing the potency of lead bioactives," explained Dr. Harry Parekh, PreveCeutical's chief research officer and lead researcher at the University of Queensland's School of Pharmacy (http://nnw.fm/ukgA1). Enhancing the stability and potency of bioactives may well enhance brain uptake, allowing peptides to bind to receptors and block pain signals.

This exciting pathway to new pain management solutions was solidified earlier this week when PreveCeutical announced the definitive agreement on the collaboration. The four-phase research program will be led by Dr. Parekh and carried out in collaboration with pain and inflammation pharmacology experts at the University of Queensland. PreveCeutical will own all intellectual property and UniQuest, the IP and research commercialization company of the University of Queensland, will receive payments for development milestones and sales-based royalties in accordance with the terms of the research agreement.

In what may become the precursor to solving the vast and vexing problems in pain management, the parties intend to commence research March 1, 2018.